173.1K XNAS Volume
XNAS 21 Apr, 2025 11:12 AM (EDT)
Generation Bio Co Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Bearish
Check Before You Buy
VIEW FULL CHECKLISTLow rank
6Positive14Negative
30.0% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Generation Bio Co Stock Price Analysis
Day Price Range | 0.4 (LTP) 0.40.4 LowHigh |
Week Price Range | 0.4 (LTP) 0.30.4 LowHigh |
Month Price Range | 0.4 (LTP) 0.30.6 LowHigh |
52 Week Price Range | 0.4 (LTP) 0.34.3 LowHigh |
Generation Bio Co Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Hit
Generation Bio Co's Revenue was higher than average estimate 2 times in past 2 years
EPS forecast
Current EPS
Avg. Estimate
Hit
EPS is expected to grow by 48.5% in FY25
Consensus Recommendation
7 ANALYST Recommendations
BUY
The consensus recommendation from 7 analysts for Generation Bio Co is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Generation Bio Co Stock Analysis
Generation Bio Co stock analysis with key metrics, changes, and trends.
Generation Bio Co Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $19.89 M | 236.92% | positive |
| |
Annual Net Profit | $131.67 M | 3.99% | negative |
| |
Price to Earning Ratio | -0.2 | - | negative |
| |
Stock Price | $0.40 | -85.71% | negative |
| |
Quarterly Revenue | $4.19 M | 45.52% | positive |
| |
Quarterly Net profit | $21.38 M | 39.23% | positive |
| |
Debt to Equity Ratio | 1.09 | - | negative |
| |
Return on Equity(ROE) | -91.02 % | -91.02% | negative |
| |
Mutual Fund Holding | 47.33 % | -0.15% | negative |
| |
Institutional Holding | 66.93 % | -0.01% | negative |
|
Loading data..
Generation Bio Co - Company Profile
What does Generation Bio Co do?
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Generation Bio Co Management structure
All Gross Remunerations are in USD
Generation Bio Co Board of directors
All Gross Remunerations are in USD